Komori
Shin Nippon Biomedical Laboratories (2395) · TargetRestatedLatest Earnings presentation (2026-08-05): "Cited as achieved"

Becoming a Partner Chosen by Customers

First written in FY2016. 29 of 35 entries say "Restated". Latest entry: 2026-08-05.

35entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2020-Q3RestatedFY2022-Q3 – FY2025-H12016: 320162017: 420172018: 320182019: 320192020: 420202021: 420212022: 320222023: 320232024: 220242025: 120252026: 52026
Same theme, other companies
Becoming Clients’ Digital Transformation PartnerA theme 20 companies write about · 0 as a headwind · 23 as a tailwind

The whole theme swung hardest in 2025: 3 of 14 companies on the "Worse" side.

0 other companies' latest entry also says "Cited as achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-05Cited as achievedEarnings presentation

    「Repeat customers account for 99%, indicating a high level of satisfaction with the quality of our services.」

    The company reported that repeat customers accounted for 99% of orders from European and U.S. customers and linked this result to recognition of its service quality.
  2. FY2026RestatedAnnual report

    「Against this business backdrop, we aim to become the “one-of-a-kind standout CRO” chosen first by customers, leveraging our strengths in supporting research and development for novel drug-discovery modalities, and are working to strengthen our systems for delivering fast, high-quality services.」

    Continues to pursue the goal of being chosen first as the “one-of-a-kind standout CRO” and strengthening systems for fast, high-quality service delivery.
  3. FY2026-H1RaisedAnnual report

    「In response to these trends, we, with a strong track record in supporting research and development for novel drug-discovery modalities, aim to become the “one-of-a-kind standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Expands the former expression “standout CRO” to the goal of becoming a “one-of-a-kind standout CRO” named first by clients.
  4. FY2025-H1RestatedAnnual report

    「In response to these trends, we, with a strong track record in supporting research and development for novel drug-discovery modalities, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Building on its track record in supporting novel drug-discovery modalities, continues to pursue the goal of becoming the “standout CRO” named first by clients through prompt responses, service improvements and improved quality.
  5. FY2024-Q3RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues to state the goal of becoming the “standout CRO” named first by clients, together with prompt responses, service improvements and improved quality.
  6. FY2024-Q2RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues to state the goal of becoming the “standout CRO” named first by clients, together with prompt responses, service improvements and improved quality.
  7. FY2024-Q1RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues to state the goal of becoming the “standout CRO” named first by clients, together with prompt responses, service improvements and improved quality.
  8. FY2023-Q3RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues to state the goal of becoming the “standout CRO” named first by clients, together with prompt responses, service improvements and improved quality.
  9. FY2023-Q2RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues to state the goal of becoming the “standout CRO” named first by clients, together with prompt responses, service improvements and improved quality.
  10. FY2023-Q1RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues the goal of becoming the “standout CRO” named first by clients through prompt responses, service improvements and improved quality.
  11. FY2022-Q3RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Continues the goal of becoming the “standout CRO” named first by clients through prompt responses, service improvements and improved quality.
  12. FY2022-Q2RaisedAnnual report

    「In response to these trends, we, whose core business is the CRO business, aim to become the “standout CRO” that clients name as their first choice, while focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality.」

    Raises the former goal of becoming a partner chosen by customers to becoming the “standout CRO” named first by clients, while also listing prompt responses, service improvements and quality improvements as the means.
  13. FY2022-Q1RestatedAnnual report

    「In response to these trends, we, whose core business is the CRO business, are focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose, with the CRO business as its core business and through prompt responses, service improvements and improved quality.
  14. FY2021RestatedAnnual report

    「In response to these trends, we are focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues to pursue the goal of becoming a partner that customers continue to choose through prompt responses, service improvements and improved quality.
  15. FY2021-Q3RestatedAnnual report

    「Outsourcing aimed at accelerating and improving the efficiency of research and development in the pharmaceutical industry remains firm in Japan and overseas. In response to these trends, we are focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, service improvements and improved quality.
  16. FY2021-Q2RestatedAnnual report

    「In response to these trends, we are focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, service improvements and improved quality.
  17. FY2021-Q1RestatedAnnual report

    「In response to these trends, we are focusing on prompt responses that meet customer needs, service improvements and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, service improvements and improved quality.
  18. FY2020ReframedAnnual report

    「Our group’s medium- to long-term management vision is to become a “one-of-a-kind company” chosen by clients in global markets through the development of a value chain, as the research and development activities of our pharmaceutical-company clients become larger in scale, more sophisticated and increasingly international.」

    Clarifies the former goal of becoming a partner chosen by customers as a medium- to long-term vision of becoming a “one-of-a-kind company” chosen in global markets.
  19. FY2020-Q3RestatedAnnual report

    「In Japan and overseas, outsourcing aimed at accelerating and improving the efficiency of research and development in the pharmaceutical industry remains firm. In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, deeper services and improved quality.
  20. FY2020-Q2RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, deeper services and improved quality.
  21. FY2020-Q1RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, deeper services and improved quality.
  22. FY2019-Q3RestatedAnnual report

    「In Japan and overseas, demand in the pharmaceutical industry remains firm for outsourcing aimed at accelerating and improving the efficiency of research and development. In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, deeper services and improved quality.
  23. FY2019-Q2RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the policy of becoming a partner that customers continue to choose through prompt responses, deeper services and improved quality.
  24. FY2019-Q1RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner that customers continue to choose.」

    Continues the goal of being a partner chosen by customers, while explicitly adding the aim of being chosen repeatedly and providing prompt responses.
  25. FY2018-Q3RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner chosen by our customers.」

    Continues to state the policy of becoming a partner chosen by customers through prompt responses, deeper services and improved quality.
  26. FY2018-Q2RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner chosen by our customers.」

    Continues to pursue the goal of becoming a partner chosen by customers through prompt responses, deeper services and improved quality.
  27. FY2018-Q1RestatedAnnual report

    「In response to these customer trends, we are focusing on prompt responses that meet customer needs, deeper services and continuous improvements in quality, with the aim of becoming a partner chosen by our customers.」

    Continues the policy of becoming a partner chosen by customers, adding prompt responses to its approach to customer needs.
  28. FY2017RestatedAnnual report

    「In response to these customer trends, we aim to become a partner chosen by our customers by deepening the services we provide to meet their needs and continuously improving service quality.」

    Continues to pursue the goal of becoming a partner chosen by customers by responding to their needs and improving service quality.
  29. FY2017-Q3RestatedAnnual report

    「In response to these customer trends, we aim to become a partner chosen by our customers by deepening the services we provide to meet their needs and continuously improving service quality.」

    Continues to state the goal of becoming a partner chosen by customers through deeper services and improved quality.
  30. FY2017-Q2RestatedAnnual report

    「In response to these customer trends, we aim to become a partner chosen by our customers by deepening the services we provide to meet their needs and continuously improving service quality.」

    Continues to pursue the goal of becoming a partner chosen by customers through deeper services and improved quality.
  31. FY2017-Q1RestatedAnnual report

    「In response to these customer trends, we aim to become a partner chosen by our customers by deepening the services we provide to meet their needs and continuously improving service quality.」

    Continues to pursue the goal of becoming a partner chosen by customers through deeper services and improved quality.
  32. FY2016First statedAnnual report

    「We aim to become a partner chosen by our customers by deepening the services we provide to meet their needs and continuously improving service quality.」

    Explicitly states the goal of competing on responsiveness to customer needs and service quality.
Moved together

"Commercializing the Nasal Delivery Platform Technology" moved the same way as this thread, in the same document, in 2 of its 35 moves.

22222★12345
  1. ★This thread
  2. 1Commercializing the Nasal Delivery Platform Technology2×
  3. 2Advanced Evaluation Facilities and Disease Models for Antibody Medicines and Regenerative Medicine2×
  4. 3Addressing Environmental and Social Issues to Achieve ESG and the SDGs2×
  5. 4Improving Preclinical Trial Efficiency through Time Value Creation2×
  6. 5Satsuma Pharmaceuticals' NASDAQ Listing2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview It last moved in the Earnings presentation of 2026-08-05: "Cited as achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.